Navigation Links
New Analysis Shows Efficacy of REMICADE(R) in Treatment of Ulcerative Colitis in Patients with Recent Disease Onset or Long-Standing Disease
Date:5/20/2008

subjects with disease duration less than three years, and 68 percent versus 34 percent for subjects with disease duration of at least three years; clinical remission: 28 percent versus 8 percent and 35 percent versus 12 percent, respectively; mucosal healing: 56 percent versus 29 percent and 63 percent versus 35 percent, respectively.

At week 30, clinical response, clinical remission and mucosal healing rates for the combined REMICADE treatment group (5 mg/kg and 10 mg/kg) were also significantly higher than the placebo group (P < 0.01) regardless of disease duration; clinical response: 49 percent versus 19 percent for subjects with disease duration less than three years, and 54 percent versus 34 percent for subjects with disease duration of at least three years; clinical remission: 28 percent versus 10 percent, and 35 percent versus 15 percent, respectively; mucosal healing: 47 percent versus 20 percent ,and 52 percent versus 32 percent, respectively. A Cochran-Mantel-Haenszel test stratified by baseline corticosteroid refractory status was used to compare REMICADE with placebo within each disease duration subgroup.

Ulcerative colitis is a chronic inflammatory disease of the colon and large intestine that affects approximately half a million Americans and can lead to frequent hospitalizations, surgery and loss of work productivity. Both UC and Crohn's disease are known collectively as inflammatory bowel diseases, or IBD. Approved in 1998 by the U.S. Food and Drug Administration as the first anti-tumor necrosis factor (TNF)-alpha therapy, REMICADE received its initial approval for the treatment of Crohn's disease and has since become the first and only anti-TNF-alpha therapy approved for the treatment of UC and pediatric Crohn's disease. A Phase 3 study evaluating the efficacy and safety of REMICADE for the treatment of pediatric UC is currently ongoing.

Impact of Anti-TNF Therapies on Absence from Work Among Employees with IBD

Also pres
'/>"/>

SOURCE Centocor
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Trubion Announces Preliminary Analysis of Phase IIb Results With TRU-015 in Rheumatoid Arthritis
2. Oncology Drugs Development Update - Worldwide Markets and Forecasts of Approved EGFr/HEr2 Inhibitors, Treatment Costs, Pathway Analysis, Current and Expanded Clinical Indications, and Novel Agents in Development
3. New Data From Large Safety Analysis of MYCAMINE Shows Favorable Clinical Safety Profile
4. Immtech Announces Interim Analysis in Phase III African Sleeping Sickness Trial
5. Analysis Shows Vernakalant Hydrochloride Injection Increases Conversion to Normal Heart Rhythm in Acute Atrial Fibrillation Patients Treated Within 48 Hours of Onset
6. New Analysis of Study Data Shows That Asacol(R) (Mesalamine) Delivers Rapid Symptom Relief for Ulcerative Colitis Patients
7. A Sociolinguistic Analysis of In-Office Dialogue Reveals Psychiatrists and Parents Have Significantly Different Perceptions on ADHD and Psychiatric Comorbidities
8. Favrille Provides Update on Timing of Analysis from Pivotal Phase 3 Clinical Trial; Reports Third Quarter 2007 Financial Results
9. Results Of VYVANSE(TM) (lisdexamfetamine dimesylate) Effect Size Analysis Presented at Major Scientific Meeting
10. Progen Presents Additional Analysis of Data from PI-88 Phase 2 Liver Cancer Study at American Association for the Study of Liver Diseases
11. Retrospective Analysis Finds That Initiation of Insulin Glargine in Patients With Type 2 Diabetes was Associated With a Lower Incidence Rate of Myocardial Infarction as Compared With NPH Insulin
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2015)... 2015   MultiVir Inc. ("MultiVir"), a clinical-stage ... candidates for the treatment of multiple oncological indications, today ... on Form S-1 with the U.S. Securities and Exchange ... of shares of its common stock. The number of ... the proposed offering have not yet been determined. MultiVir ...
(Date:3/30/2015)... Sorrento Therapeutics, Inc. (Nasdaq: SRNE ) ... to the position of Executive Vice President & ... be responsible for all legal, compliance and intellectual property ... BioDelivery Sciences International, Inc., where he was Senior Vice ... management that led that company to over a six ...
(Date:3/30/2015)... 30, 2015 Alere Inc. (NYSE: ALR ... following statement today in support of President Barack ... "As the global leader in rapid ... Obama for establishing a National Action Plan with ... threat of antibiotic resistance. We look forward to continuing ...
Breaking Medicine Technology:MultiVir Files Registration Statement for Proposed Initial Public Offering 2Sorrento Announces Appointment Of George Ng As EVP & Chief Legal Officer 2Sorrento Announces Appointment Of George Ng As EVP & Chief Legal Officer 3Alere Applauds President's National Action Plan to Combat Antibiotic-Resistant Bacteria 2
... Poster Presented at ASCO Annual Meeting -, ... May 31 /PRNewswire-FirstCall/,-- Poniard Pharmaceuticals, Inc. (Nasdaq: ... oncology, today presented preliminary safety and,efficacy data ... of picoplatin in,combination with docetaxel and prednisone, ...
... ... Other Organs-, -All Patients Surpassed Expected Median Survival Time at Lowest Planned ... ... PPHM ) today reported that clinical,researchers from the Abramson Cancer Center of the University ...
Cached Medicine Technology:Poniard Announces Positive First-Line Efficacy and Safety Data From Ongoing Phase 2 Trial of Picoplatin in Patients with Metastatic Hormone Refractory Prostate Cancer 2Poniard Announces Positive First-Line Efficacy and Safety Data From Ongoing Phase 2 Trial of Picoplatin in Patients with Metastatic Hormone Refractory Prostate Cancer 3Poniard Announces Positive First-Line Efficacy and Safety Data From Ongoing Phase 2 Trial of Picoplatin in Patients with Metastatic Hormone Refractory Prostate Cancer 4Data To Be Presented at ASCO Supports Potential of Peregrine's Cotara(R) for the Treatment of Brain Cancer 2Data To Be Presented at ASCO Supports Potential of Peregrine's Cotara(R) for the Treatment of Brain Cancer 3Data To Be Presented at ASCO Supports Potential of Peregrine's Cotara(R) for the Treatment of Brain Cancer 4Data To Be Presented at ASCO Supports Potential of Peregrine's Cotara(R) for the Treatment of Brain Cancer 5
(Date:3/30/2015)... Rosa, CA (PRWEB) March 30, 2015 KIND ... of LED grow light products in 2015. The excellent value ... enabled them to take the pole position in the race ... leading feature of the KIND LED suite of grow lights ... the most plant-friendly Photosynthetic Active Radiation (PAR) wavelengths that plants ...
(Date:3/30/2015)... Health Fitness Revolution, founded by renowned fitness expert and ... has created a new list of the Top 13 ... fittest leaders in terms of physical fitness, health and wellness. ... kind to detail the health and fitness habits of reigning ... profiled on the list are Israel’s Benjamin Netanyahu, Russia’s Vladimir ...
(Date:3/30/2015)... Lake City, Itah (PRWEB) March 30, 2015 ... health insurance reimbursement for small businesses, announced its ... You?" is available on webcast. This discussion was ... , According to Zane Benefits, there is ... by small businesses. Instead of selecting a group ...
(Date:3/30/2015)... 30, 2015 A new Zofran lawsuit ... Superior Court on behalf of a child who was ... his mother was prescribed the anti-nausea medication during the ... filing in Alameda Superior Court, the baby’s mother was ... she experienced in the early months of her pregnancy. ...
(Date:3/30/2015)... “ iCareTech ” was featured on NewsWatch ... look at the latest and coolest technology products and services ... technology expert, conducted the review and shared with viewers how ... the medical and health fields. , Wearable technology has been ... past couple of years. Well, at CES, NewsWatch TV came ...
Breaking Medicine News(10 mins):Health News:Best LED Grow Lights of 2015 Are Being Led By KIND LED 2Health News:The Top 13 Fittest Heads of State: Why Putin Might Be No. 1 in Health and Fitness 2Health News:Zane Benefits New Webinar Premium Reimbursement Webinar Now Available On-Demand 2Health News:New Zofran Lawsuit Alleging Birth Defects Filed This Month in California Superior Court 2Health News:New Zofran Lawsuit Alleging Birth Defects Filed This Month in California Superior Court 3Health News:New Zofran Lawsuit Alleging Birth Defects Filed This Month in California Superior Court 4Health News:World’s First Medical Intelligent Band was Featured on NewsWatch Television on January 30, 2015 2
... , , WALTHAM, ... (MRG), the global authority on medical technology market intelligence, ... cuts to reimbursement for hospital-acquired infections are resulting in ... central venous catheters (CVCs). MRG,s US Markets for ...
... CROFTON, Md., July 22 Dr. Robert Graw announced Nighttime Care ... the Muddy Branch Square Shopping Center at 882 Muddy Branch Road, ... year to serve children and adults when residents do not have ... and prescription services. , , "This ...
... , , REDWOOD ... announced positive results from its first Phase 2 clinical ... of its ARX-01 Sufentanil NanoTab(TM) PCA System for management ... during hospitalization. Patients reliably self-administered sufentanil NanoTabs repeatedly over ...
... , , Increased Volume Drives Revenue Growth Despite ... Improved Gross Margin Percent , Earnings Rise 20% to $1.06 (reported); ... Reported EPS Guidance ... Pro forma non-GAAP EPS Guidance Range Raised to $4.20 to $4.30 per share , ...
... ... a competitive advantage Fastrack has introduced new functionality to its, Enterprise System that will ... features designed to help manage critical business processes that will improve productivity and reduce ... ...
... ... announced a successful demonstration of five community-based health information exchange (HIE) projects in ... information to improve patient care. , ... San Francisco, CA (PRWEB) July 20, 2009 -- ...
Cached Medicine News:Health News:Following CMS Cuts to Reimbursement for Medical Errors, New Devices Aimed at Reducing Nosocomial Infections Emerge 2Health News:Following CMS Cuts to Reimbursement for Medical Errors, New Devices Aimed at Reducing Nosocomial Infections Emerge 3Health News:Nighttime Care Centers Announces New Urgent Care Medical Clinic in Montgomery County, Maryland 2Health News:AcelRx Announces Perfect Performance of Handheld Component of ARX-01 Sufentanil NanoTab PCA System in a Phase 2 Study 2Health News:AcelRx Announces Perfect Performance of Handheld Component of ARX-01 Sufentanil NanoTab PCA System in a Phase 2 Study 3Health News:Lilly Reports Solid Second-Quarter 2009 Results, Raises EPS Guidance 2Health News:Lilly Reports Solid Second-Quarter 2009 Results, Raises EPS Guidance 3Health News:Lilly Reports Solid Second-Quarter 2009 Results, Raises EPS Guidance 4Health News:Lilly Reports Solid Second-Quarter 2009 Results, Raises EPS Guidance 5Health News:Lilly Reports Solid Second-Quarter 2009 Results, Raises EPS Guidance 6Health News:Lilly Reports Solid Second-Quarter 2009 Results, Raises EPS Guidance 7Health News:Lilly Reports Solid Second-Quarter 2009 Results, Raises EPS Guidance 8Health News:Lilly Reports Solid Second-Quarter 2009 Results, Raises EPS Guidance 9Health News:Lilly Reports Solid Second-Quarter 2009 Results, Raises EPS Guidance 10Health News:Lilly Reports Solid Second-Quarter 2009 Results, Raises EPS Guidance 11Health News:Lilly Reports Solid Second-Quarter 2009 Results, Raises EPS Guidance 12Health News:Lilly Reports Solid Second-Quarter 2009 Results, Raises EPS Guidance 13Health News:Lilly Reports Solid Second-Quarter 2009 Results, Raises EPS Guidance 14Health News:Lilly Reports Solid Second-Quarter 2009 Results, Raises EPS Guidance 15Health News:Lilly Reports Solid Second-Quarter 2009 Results, Raises EPS Guidance 16Health News:Lilly Reports Solid Second-Quarter 2009 Results, Raises EPS Guidance 17Health News:Lilly Reports Solid Second-Quarter 2009 Results, Raises EPS Guidance 18Health News:Lilly Reports Solid Second-Quarter 2009 Results, Raises EPS Guidance 19Health News:Lilly Reports Solid Second-Quarter 2009 Results, Raises EPS Guidance 20Health News:Fastrack Automates Workflow For Homecare Providers 2Health News:Fastrack Automates Workflow For Homecare Providers 3Health News:CAeHC Demonstrates NHIN-enabled Gateways Among Five California Health Information Exchanges 2Health News:CAeHC Demonstrates NHIN-enabled Gateways Among Five California Health Information Exchanges 3Health News:CAeHC Demonstrates NHIN-enabled Gateways Among Five California Health Information Exchanges 4Health News:CAeHC Demonstrates NHIN-enabled Gateways Among Five California Health Information Exchanges 5Health News:CAeHC Demonstrates NHIN-enabled Gateways Among Five California Health Information Exchanges 6
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: